However, up to date, targeting the most commonly mutated genes KRAS and P53 in pancreatic cancer has not yet produced one promising clinical therapeutic (Thomas and Radhakrishnan, 2019), which is mainly because of the targeted delivery problems. This evidence concerns the gene KRAS and familial pancreatic carcinoma.